NASDAQ:DCPH Deciphera Pharmaceuticals (DCPH) News Today $14.02 +0.04 (+0.29%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$13.67▼$14.1050-Day Range$13.28▼$15.9652-Week Range$10.14▼$22.76Volume627,585 shsAverage Volume444,266 shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice Target$21.78 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address DCPH Media Mentions By Week DCPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DCPH News Sentiment▼1.150.87▲Average Medical News Sentiment DCPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DCPH Articles This Week▼52▲DCPH Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCalculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)finance.yahoo.com - June 9 at 10:24 AMMartingale Asset Management L P Purchases 28,059 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)marketbeat.com - June 6 at 7:55 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $21.78 Consensus PT from Brokeragesamericanbankingnews.com - June 6 at 1:20 AMJMP Securities Reiterates Deciphera Pharmaceuticals (DCPH) Market Outperform Recommendationmsn.com - June 5 at 3:26 PMCitigroup Inc. Lowers Stock Holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)marketbeat.com - May 26 at 5:37 AMEquities Analysts Offer Predictions for Deciphera Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:DCPH)americanbankingnews.com - May 20 at 2:22 AMDeciphera Pharmaceuticals (NASDAQ:DCPH) Stock Price Up 7.8% After Insider Buying Activityamericanbankingnews.com - May 17 at 1:10 AMSG Americas Securities LLC Has $156,000 Stock Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)marketbeat.com - May 14 at 4:20 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Average Rating of "Moderate Buy" by Analystsamericanbankingnews.com - May 14 at 2:50 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Director Dennis Leo Walsh Buys 11,000 Sharesmarketbeat.com - May 12 at 5:48 PMHC Wainwright Weighs in on Deciphera Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:DCPH)americanbankingnews.com - May 9 at 4:18 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Rating of "Moderate Buy" from Analystsmarketbeat.com - May 9 at 3:20 AMQ2 2023 EPS Estimates for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Decreased by Analystamericanbankingnews.com - May 9 at 2:38 AMJonesTrading Remains a Hold on Deciphera Pharmaceuticals (DCPH)markets.businessinsider.com - May 8 at 4:15 PMDeciphera Pharmaceuticals, Inc. Forecasted to Post FY2023 Earnings of ($2.59) Per Share (NASDAQ:DCPH)marketbeat.com - May 8 at 3:36 AMStifel Nicolaus Trims Deciphera Pharmaceuticals (NASDAQ:DCPH) Target Price to $14.00americanbankingnews.com - May 7 at 7:10 AMDeciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcriptseekingalpha.com - May 7 at 4:58 AMDeciphera Pharmaceuticals Stock (NASDAQ:DCPH), Dividendsbenzinga.com - May 5 at 12:13 PMFY2026 EPS Estimates for Deciphera Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:DCPH)marketbeat.com - May 5 at 8:27 AMDeciphera Pharmaceuticals (NASDAQ:DCPH) Announces Quarterly Earnings Resultsamericanbankingnews.com - May 5 at 7:26 AMDeciphera Pharmaceuticals (NASDAQ:DCPH) Shares Gap Down to $14.30americanbankingnews.com - May 5 at 6:02 AMDeciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com - May 3 at 2:16 PMRecap: Deciphera Pharmaceuticals Q1 Earningsmsn.com - May 3 at 8:43 AMDeciphera Pharmaceuticals Announces First Quarter 2023 Financial Resultsfinance.yahoo.com - May 3 at 8:43 AMWhat Wall Street expects from Deciphera Pharmaceuticals's earningsmarkets.businessinsider.com - May 2 at 6:26 PMSVB Leerink Equities Analysts Cut Earnings Estimates for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)americanbankingnews.com - April 28 at 6:32 AMDeciphera Pharmaceuticals, Inc. to Post FY2025 Earnings of $0.26 Per Share, SVB Leerink Forecasts (NASDAQ:DCPH)americanbankingnews.com - April 28 at 5:48 AMWill Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q1 Earnings? What You Should Knowfinance.yahoo.com - April 26 at 1:55 PMDeciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023finance.yahoo.com - April 26 at 8:54 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Up 6.9% in Marchmarketbeat.com - April 21 at 4:25 PMThere Is A Reason Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Price Is Undemandingfinance.yahoo.com - April 18 at 7:25 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Rating of "Moderate Buy" from Brokeragesamericanbankingnews.com - April 14 at 6:14 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Average Recommendation of "Moderate Buy" by Analystsmarketbeat.com - April 14 at 6:13 AMDeciphera Pharmaceuticals, Inc.(DCPH) Investor Presentation - Slideshowseekingalpha.com - March 31 at 9:57 AMDeciphera Pharmaceuticals: In The Middle Of A Major Comeback (Upgrade)seekingalpha.com - March 27 at 2:46 PMSteven L. Hoerter Sells 7,500 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Stockamericanbankingnews.com - March 25 at 5:42 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Sold by Hennion & Walsh Asset Management Inc.marketbeat.com - March 23 at 5:19 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $22.22 Consensus Target Price from Brokeragesamericanbankingnews.com - March 23 at 1:40 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Consensus Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - March 20 at 4:25 AMDeciphera Pharmaceuticals: INTRIGUE Phase 3 Shows Substantial Benefitseekingalpha.com - March 18 at 5:21 AMDeciphera Pharmaceuticals (DCPH) Investor Presentation - Slideshowseekingalpha.com - March 17 at 3:00 PMWhy Deciphera Pharmaceuticals Stock Jumped This Weekmsn.com - March 16 at 6:16 PMDeciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?finance.yahoo.com - March 14 at 7:01 AMJacobs Levy Equity Management Inc. Has $24.26 Million Stock Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)marketbeat.com - March 10 at 9:25 AMWhy Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 7.1% Since Last Earnings Report?finance.yahoo.com - March 9 at 3:15 PMNuveen Asset Management LLC Increases Stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)marketbeat.com - March 7 at 4:41 AMDeciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCTfinance.yahoo.com - March 1 at 8:37 AMArmistice Capital LLC Has $88.21 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)marketbeat.com - February 24 at 10:49 AMDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) EVP Sells $14,662.10 in Stockmarketbeat.com - February 17 at 4:18 PMBank Of America Now Owns 0.40% of Deciphera Pharmaceuticals (DCPH)nasdaq.com - February 16 at 3:31 PM Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VERV News Today AVDL News Today MNKD News Today KNSA News Today MRUS News Today MIRM News Today DAWN News Today OPK News Today CRNX News Today CTIC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:DCPH) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.